Results 81 to 90 of about 678,613 (312)

CD40 antibody as an adjuvant induces enhanced T cell responses

, 2004
Monoclonal antibodies against CD40, conjugated to antigen, act as potent immunological adjuvants for primary antibody responses. We show here that CD40mAbs can also act as strong adjuvants for memory antibody responses, and for T cell responses as ...
Heath, A.W., Carlring, J., Barr, T.A., McCormick, A.L.   +3 more
core   +2 more sources

PB2114: TREATMENT RESULTS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FROM HIGH-RISK GROUP

HemaSphere, 2022
K. Filonenko, I. Kriachok, A. Martynchyk, I. Titorenko, Y. Stepanishyna, O. Aleksyk, K. Ukianchenko, I. Pastushenko, Y. Kushchevyy, O. Novosad, O. Karnabeda, I. Diagil, V. Kozlov   +12 more
doaj   +1 more source

Adjuvant synergy: the effects of nasal coadministration of adjuvants

, 2004
Modern peptide and protein subunit vaccines suffer from poor immunogenicity and require the use of adjuvants. However, none of the currently licensed adjuvants can elicit cell-mediated immunity or are suitable for mucosal immunization.
Alpar, H.O., Bramwell, V.W., Moschos, S.A., Somavarapu, S.   +3 more
core   +1 more source

Paclitaxel induces NM2‐dependent cellular contraction through GEF‐H1 dissociation from microtubules and RhoA/ROCK activation in cancer cells

Molecular Oncology, EarlyView.
Taxanes are widely used chemotherapeutics whose effects on cellular mechanics remain poorly understood. We show that paclitaxel induces rapid cellular contraction by promoting GEF‐H1 dissociation from microtubules and non‐muscle myosin II activation through RhoA/ROCK.
Gloria Asensio‐Juárez, Rafael Pérez‐Díaz, Hugo Ramos‐Solano, Marina Garrido‐Casado, Vanessa C. Talayero, Miguel Vicente‐Manzanares   +5 more
wiley   +1 more source

Development of Nonaggregating Poly-A Tailed Immunostimulatory A/D Type CpG Oligodeoxynucleotides Applicable for Clinical Use

Journal of Immunology Research, 2015
Immunostimulatory CpG ODNs have been developed and utilized as TLR9-dependent innate immune activators and vaccine adjuvants. Four different types of immunostimulatory CpG ODNs (A/D, B/K, C, and P type) have been reported. A/D type ODNs are characterized
Taiki Aoshi, Yasunari Haseda, Kouji Kobiyama, Hirotaka Narita, Hideaki Sato, Hirokazu Nankai, Shinichi Mochizuki, Kazuo Sakurai, Yuko Katakai, Yasuhiro Yasutomi, Etsushi Kuroda, Cevayir Coban, Ken J. Ishii   +12 more
doaj   +1 more source

Host- and Microbe-Dependent Dietary Lipid Metabolism in the Control of Allergy, Inflammation, and Immunity

Frontiers in Nutrition, 2019
The intestine is the largest immune organ in the body, provides the first line of defense against pathogens, and prevents excessive immune reactions to harmless or beneficial non-self-materials, such as food and intestinal bacteria.
Azusa Saika, Azusa Saika, Takahiro Nagatake, Jun Kunisawa, Jun Kunisawa, Jun Kunisawa, Jun Kunisawa, Jun Kunisawa   +7 more
doaj   +1 more source

The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: A Phase I trial in Taiwan

, 2014
Background: Avian H5N1 influenza has caused human infections globally and has a high mortality rate. Rapid production of effective vaccines is needed. Methods: A phase 1, randomized, observer-blinded clinical trial was conducted to examine the safety ...
Pan, Sung-Ching;Kung, Hsiang-Chi;Kao, Tsui-Mai;Wu, Hsio;Dong, Shao-Xing;Hu, Mei-Hua;Chou, Ai-Hsiang;Chong, Pele;Hsieh, Szu-Min;Chang, Shan-Chwen
core   +1 more source

Extracellular matrix remodeling and immune reprogramming drive residual tumor progression of liver cancer after incomplete microwave ablation

Molecular Oncology, EarlyView.
Incomplete microwave ablation (iMWA) of liver cancer triggers a biphasic progression in residual tumors. At Day 3, the microenvironment is characterized by acute inflammatory responses and extracellular matrix (ECM) remodeling. By Day 14, a profound shift occurs toward oncogenic signal transduction and immunosuppression, marked by macrophage ...
Yu Liu, Yubei He, Nikolaus Berndt, Michael Mülleder, Kathrin Textoris‐Taube, Jing Guo, Matthias Stechele, Justus Ramtke, Shraga Nahum Goldberg, Lynn Jeanette Savic   +9 more
wiley   +1 more source

Correction to: Vaccination with nanoparticles combined with micro-adjuvants protects against cancer

Journal for ImmunoTherapy of Cancer, 2019
Following publication of the original article [1], the author reported an author’s family name has been misspelled. Paul Engroff should be replace Paul Engeroff.
Mona O. Mohsen, Matthew D. Heath, Gustavo Cabral-Miranda, Cyrill Lipp, Andris Zeltins, Marcos Sande, Jens V. Stein, Carsten Riether, Elisa Roesti, Lisha Zha, Paul Engeroff, Aadil El-Turabi, Thomas M. Kundig, Monique Vogel, Murray A. Skinner, Daniel E. Speiser, Alexander Knuth, Matthias F. Kramer, Martin F. Bachmann   +18 more
doaj   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source